Other News

Lucem Health Introduces Reveal for Stroke to Accelerate Treatment of AFib-Related Stroke Risks

Rhythm by Comments are Disabled

Groundbreaking Solution Identifies Undiagnosed AFib and Speeds Treatments Proven to Prevent Strokes
DAVIDSON, N.C., Dec. 13, 2023 /PRNewswire/ — Lucem Health™, a leader in AI-driven early disease detection solutions, announced today the release of Reveal for Stroke, an innovative solution designed to identify patients with undocumented atrial fibrillation (AFib) and higher risk of AFib-related strokes. As noted by the American Heart Association, AFib affects 2.7-6.1 million individuals in the US and significantly increases the risk of ischemic stroke. Thus, the need for early identification and intervention has never been more critical.
AFib-related strokes constitute approximately 15-20% of all ischemic strokes. However, at least one-in-five AFib cases remain undocumented in clinical practice, leading to many patients missing out on important stroke prevention treatment. Reveal for Stroke aims to close this gap by accurately identifying patients with previously undiagnosed AFib and Atrial Flutter, thereby enabling timely preventive care.
Reveal for Stroke leverages existing ECG and other clinical data that already exists in patient records. The solution identifies adults ages 22 and above with undiagnosed AFib or Atrial Flutter and calculates each patient’s CHA2DS2-VASc score to assess stroke risk comprehensively. Reveal for Stroke enables timely and appropriate treatment by presenting clinicians with an FDA-cleared AccurECG™ analysis, stroke risk scores, and HAS-BLED assessments for major bleeding risks – all vital data points for making informed, effective clinical decisions.
Remarkably, Reveal for Stroke surfaces up to 95% of previously unidentified AFib patients. By getting patients on the right treatment pathways–which may include blood thinners, ablation therapy, and implantables–stroke risk can be reduced by about 70% in patients with AFib.
“At Lucem Health, we develop solutions that identify patients with major health risks that are hiding in plain sight. Reveal for Stroke reflects that commitment by bringing actionable stroke risk insights into everyday practice, highlighting patients who need care and thus saving lives, without changing clinical workflows,” says Jeremy E. Pierotti, General Manager of Solutions at Lucem Health.
Lucem Health has partnered with AccurKardia, a renowned ECG-led diagnostics company, to develop Reveal for Stroke. AccurKardia’s proprietary AccurECG™ Analysis System is an FDA-cleared, HIPAA-compliant, device-agnostic, and fully automated ECG interpretation software solution. This state-of-the-art system is capable of detecting 13 different arrhythmias with exceptional accuracy, empowering healthcare organizations to effectively prioritize patients for early interventions.
“Reveal for Stroke represents a shared vision with Lucem Health to harness the full potential of ECG data in managing stroke risks. Our combined efforts have produced an easy-to-implement tool that is as clinically impactful as it is user-friendly, marking an advance in patient-centric care,” says Juan C. Jimenez, CEO of AccurKardia. 
About Lucem Health Lucem Health helps healthcare providers accelerate disease detection and treatment using practical, responsible AI, so they can improve patients’ lives and increase the clinical and financial yield from today’s scarce care delivery resources. We envision a world in which clinicians detect problems before they become life-threatening and patients get world-class care, everywhere. Learn more at www.lucemhealth.com.
About AccurKardia AccurKardia is an ECG-led diagnostics software company unlocking the value of the ECG signal for broad diagnostics coverage and disease management ultimately improving clinical outcomes and saving lives at a planetary scale. AccurKardia’s first FDA-cleared product, AccurECG (Class II SaMD), is a cloud-based and device-agnostic software for fully automated ECG interpretation and detection for up to 13 arrhythmias. The technology assists cardiac monitoring companies in the analysis of ECGs recorded from holters, event recorders, and cardiac telemetry devices. The Company completed Cohort 3 of Mayo Clinic Platform_Accelerate in July 2023. For more information about AccurKardia, please visit: https://www.accurkardia.com/.
Media Contacts:Lucem HealthOscar Eclov-ReherDirector of Marketing[email protected]
AccurKardiaNicole Brunetnicole@wearesubstrate.com
SOURCE Lucem Health

Continue Reading →

Society of NeuroInterventional Surgery Congratulates President Mahesh Jayaraman, MD, FACR, on Appointment as Chair of Department of Diagnostic Imaging at Brown’s Warren Alpert Medical School

Neuro by Comments are Disabled

FAIRFAX, Va., Dec. 13, 2023 /PRNewswire/ — The Society of NeuroInterventional Surgery (SNIS) congratulates SNIS President Mahesh Jayaraman, MD, FACR, on his promotion to Chair of the Department of Diagnostic Imaging at The Warren Alpert Medical School of Brown University and Chief of Diagnostic Imaging at Lifespan, effective January 1, 2024. He will also be appointed the Charles and Elfriede Collis-Frances Weeden Gibson Professor of Diagnostic Imaging.
“I’m thrilled to congratulate Dr. Jayaraman on this well-deserved promotion. His groundbreaking research, strong leadership, and endless dedication to pursuing excellence makes him an invaluable asset to our field,” said SNIS Executive Director Marie Williams Denslow. “We are very grateful for his hard work, contributions, and commitment to his patients, and wish him success in his new roles.”
Dr. Jayaraman is recognized as a pioneering interventional neuroradiologist; his work has been published in more than 150 peer-reviewed journal articles, books and book chapters. He also serves as a Professor of Diagnostic Imaging, Neurology, and Neurosurgery at The Warren Alpert Medical School and the Director of the Neurovascular Center at Rhode Island Hospital. Under his direction, the center has gained international acclaim for providing cutting-edge care for patients with cerebrovascular disease.
As president of SNIS, Dr. Jayaraman leads SNIS in all its endeavors to enhance the field. Together SNIS members work to promote research, standard-setting, education and advocacy regarding diagnosing and treating diseases of the brain, spine, head and neck. With more than 1,000 members worldwide, the society is committed to providing the highest quality of patient care through these minimally invasive procedures.
Outside of his clinical work, Dr. Jayaraman has helped lead the SNIS effort to update stroke protocols across the nation through the association’s Get Ahead of Stroke® campaign. These policy changes help ensure that patients experiencing a severe stroke are transported directly to a Level 1 stroke center by EMS personnel. He championed this work in Rhode Island, resulting in statewide policy changes in 2016.
About the Society of NeuroInterventional Surgery
The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head and neck. Visit www.snisonline.org and follow us on Twitter (@SNISinfo) and Facebook (@SNISOnline).
SOURCE The Society of NeuroInterventional Surgery (SNIS)

Continue Reading →

Implicity Joins the AWS ISV Accelerate Program

Financial by Comments are Disabled

This milestone will fuel Implicity’s rapid US expansion by providing valuable co-sell support and benefits including seamless integration, increased reliability, and expanded access to AWS services
CAMBRIDGE, Mass., Dec. 13, 2023 /PRNewswire/ — IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. The program helps AWS partners drive new business by directly connecting participating ISVs with the AWS Sales organization.
“This is an important milestone that amplifies our reach and validates our mission to bring digital innovation to cardiology. By deepening our relationship with AWS, we can help even more clinicians improve cardiac care by delivering cutting-edge solutions that enable more efficient and effective remote monitoring,” said Jon Hunt, PhD., Implicity’s Chief Commercial Officer in North America.
Implicity’s AI-powered* platform allows healthcare professionals to better manage the growing streams of patient information being produced by cardiac implantable electronic devices (CIEDs), such as pacemakers and implanted defibrillators. The solutions can also interpret data and automatically alert care teams when intervention is required.
The AWS ISV Accelerate Program provides Implicity with co-sell support that enables partners to meet customer needs through collaboration with AWS field sellers globally. Co-selling provides better customer outcomes and assures mutual commitment from AWS and its partners.
“Before Implicity, our team would have spent hours weeding through alerts and reports. This would have delayed the treatment of patients with clinically significant events or critical episodes. Additionally, their customer support and service has been second to none. They are truly dedicated to helping clinicians streamline their care and optimize their workflow. This system is life-changing,” said Dan Morris, Device Clinic Lead at the Heart Center of Nevada.
AWS ISV Accelerate program members are held to the industry’s highest standards. To gain acceptance into the AWS ISV Accelerate Program, proof of customer excellence was required to validate the success users have experienced using the technology. Implicity also had to pass a rigorous technical and security review of its platform to ensure the quality and design of its solutions. The program gives Implicity-focused co-selling support and access to expanded sales enablement resources from AWS. It also provides technical enablement and business resources to enhance Implicity’s offerings and drive innovation.
About ImplicityImplicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.
Implicity’s platform provides critical health information augmented by FDA-cleared AI* algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub**, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe. To learn more, visit www.implicity.com
*FDA cleared Class II medical device and CE marked Class I (under MDD) medical device; see the instructions for use for more information. 
**Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes
Media Contact:Andrea LePaineMedia Junction[email protected]m
SOURCE Implicity

Continue Reading →

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Coronary/Structural Heart by Comments are Disabled

TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment […]

Continue Reading →

Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation

Rhythm by Comments are Disabled

AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met: 99.9% probability of superiority over placebo
AP31969, a novel compound being developed for sinus rhythm maintenance in atrial fibrillation, commences dosing in phase 1

COPENHAGEN, Denmark, Dec. 13, 2023 /PRNewswire/ — Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces the publication of data in Nature Medicine with the full results from its Phase 2 proof-of-concept trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. As previously announced, the trial met its primary endpoint, thereby demonstrating the first ever proof mechanism for SK channel inhibition as a novel treatment for AF.
AP30663 Phase 2 trial results
In the trial, patients with a current episode of AF lasting for seven days or less were randomized to receive an intravenous infusion of 3 or 5 mg/kg of AP30663 or placebo. The primary endpoint of the trial was cardioversion from AF to sinus rhythm within 90 min from the start of the intravenous infusion, analysed using Bayesian statistics.
The primary endpoint occurred in 42% (5 of 12), 55% (12 of 22) and 0% (0 of 25) of patients treated with 3 mg/kg AP30663, 5 mg kg/1 AP30663, or placebo, respectively. Both doses demonstrated more than 99.9% probability of superiority over placebo, surpassing the prespecified 95% threshold. No ventricular arrhythmias were observed, and adverse event rates were comparable between active and placebo group. The results are now published in the high-impact journal Nature Medicine (https://www.nature.com/articles/s41591-023-02679-9).
AP31969 Phase 1 trial initiated
In addition to the publication of the above phase 2 trial results, the company has also successfully dosed the first healthy volunteer subjects in a phase 1, first-human-dose, clinical trial of AP31969, an oral first-in-class SK ion channel inhibitor designed to maintain sinus rhythm in patients suffering from AF.
The phase 1 trial is planned to consist of two parts: single ascending dose and multiple ascending dose. In addition, the effect of food on the absorption of the compound will be investigated. Results from the trial are expected in Q3 2024.
AP31969 is being developed for chronic oral maintenance treatment to prevent AF recurrence (maintain sinus rhythm) and has shown strong pre-clinical efficacy combined with a promising safety profile.
Anders Gaarsdal Holst, MD, PhD, Chief Executive Officer of Acesion, said “We are pleased that Nature Medicine has recognised the importance of our AP30663 results for conversion of AF to sinus rhythm and accepted them for publication in their prestigious journal. Based on this achievement of clinical proof-of-mechanism, and enabled by our recent successful Series B financing, we  have now also moved our oral SK inhibitor AP31969 into clinical development. Through this study, we will learn about the safety, as well as the pharmacokinetics of AP31969 and it is an important step towards addressing the large unmet need within atrial fibrillation.”
AF is the most common type of cardiac arrhythmia and is forecast to affect 25 million people in the US and EU by 2030. Existing drug therapies for AF are associated with the risk of serious cardiac or other adverse effects, resulting in a great need for safer drugs. Yet, there has been a lack of innovation and development with no new chronic AF drug approved for nearly 20 years. With AP31969, Acesion is aiming to develop a safer alternative.
About Acesion Pharma
Acesion builds on 20 years of know-how with development of small-molecule SK inhibitors and is the world leader in the field of SK channel inhibition, being the only company able to identify and progress SK channel inhibitors into clinical trials. In pre-clinical studies, inhibiting the SK channels has been shown to result in pronounced antiarrhythmic effects in the atria while avoiding effects on the ventricles, the major chambers of the heart and the source of most safety issues with existing drugs. Furthermore, the SK channel has strong genetic validation, with genes encoding the SK channels having one of the strongest associations to AF in human genome-wide association studies. Acesion’s AP30663 IV is a short acting conversion therapy that has completed a phase 2 trial proving the value of this first-in-class mechanism in AF and thereby de-risking Acesion’s broader SK inhibitor pipeline. Acesion’s oral program with lead candidate AP31969 is designed and engineered using in house knowhow to optimise for, and meet, very high hurdles in both efficacy and particularly safety where existing treatments fall short of patient needs. Acesion Pharma is backed by Novo Holdings, Canaan, Alpha Wave Ventures, Global BioAccess Fund, Wellcome Trust, Broadview Ventures and FC Capital.
https://www.acesionpharma.com/ 
About atrial fibrillation (AF)
AF is the most common type of cardiac arrhythmia mainly affecting the elderly population. Lifetime risk for development of AF is estimated at more than one in three. It is forecast to affect 25 million people in the US and EU by 2030. AF is characterized by chaotic electrical activity in the upper chambers of the heart, the atria, resulting in an irregular and high heart rate. AF is associated with impaired quality of life, increased rate of hospitalization, and a five-fold increased risk of stroke. Increasing evidence suggests that patients with AF also face a higher risk of cognitive dysfunction and dementia.
AF is often treated by electrical shock to bring the heart back to its normal rhythm (conversion). This requires general anesthesia in a hospital setting. In addition, many patients are likely to benefit from chronic treatment to prevent AF and maintain normal sinus rhythm. Existing drug therapies for cardioversion or prevention of AF are associated with risk of serious cardiac or other adverse effects, resulting in a great need for safer drugs. Yet, there has been a lack of innovation and development with no new chronic AF drug approved for nearly 20 years. A landmark New England Journal of Medicine published clinical trial (https://doi.org/10.1056/NEJMoa2019422) has shown that sinus rhythm maintenance treatment improves survival and long-term outcomes for AF patients.
SOURCE Acesion Pharma

Continue Reading →

SYNDEO Medical Named by Business Worldwide Magazine as one of 2023’s Top 20 Most Innovative Companies to Watch

Financial by Comments are Disabled

LONDON, Dec. 13, 2023 /PRNewswire/ — Belgium-based medical device design company SYNDEO Medical has made Business Worldwide Magazines 2023 “20 Most Innovative Companies to Watch” list. The list is a celebration of trailblazing organizations that are changing the game in their respective industries and altering the corporate landscape. Encompassing healthcare, banking, industry, construction, energy, and more, these companies are at the cutting edge of breakthrough technologies, innovation and modernized business structures. Those included in the list demonstrate a shared goal of developing revolutionary products and technology that drive scalable business models and disrupt established industries and markets.
Led by Justin Lampropoulos, the company is on a mission to revolutionise the way healthcare practitioners access tools they need, by bridging the gap between past and future.
At the heart of every operating theatre lies a combination of essential tools and materials needed to save and improve lives. Everything from surgical gloves to gowns, scalpels and intricate medical devices are brought together for every specific surgery, and for decades these were all conveniently provided in customised, sterile packs. This tailor-made approach worked for medical teams, and it’s what they came to expect, but over the past five to seven years custom packs have become virtually extinct due to reduced funding and other external pressures.
On average, every pack contains about 30/40 different components, which means those involved in hospital procurement have to buy all of those products independently, fly them, manage the purchase orders, and deliver. The complexity of producing an additional 10-15 purchase orders with the associated contracts and sales representatives puts a huge strain on patient care, finances, and overall efficiency.  Doctors and nurses were spending hours shopping for specific items of equipment when they want to be focusing on patient care, so it became clear that a new solution was needed.
SYNDEO Medical stepped in to reinvent the approach that combined the affordability and scalability needed to meet modern pressures with the flexibility, choice and familiarity associated with traditional packs.
Focusing on radiology and cardiology, SYNDEO packs combine all the time-saving advantages of standardised packs with a tailored selection based on specific interventional healthcare needs. The company has partnered with healthcare professionals to create customised procedural solutions that are both efficient and improve patient outcomes.
The SYNDEO approach also saves money, thanks to a revolutionary pricing model. As a result, medical teams often find themselves paying as little as 70% less than they were on standard packs.
Approximately 80% of the components are manufactured and assembled in-house, in direct collaboration with SYNDEO’s strategic partners. This gives the company complete control of the entire process, enabling the team to maintain consistently high standards and manage supply chain speeds, establishing SYNDEO as a company that challenges the status quo.
SYNDEO’s packs also help healthcare departments reduce waste. Because the tools needed for one surgery may be completely different to the next, many packs contain unused items which end up in landfill.  The customised approach means that medical departments only get the tools they need. The company also offers a new line of green and sustainable eco products, all with a great biodegradability profile.
To learn more about how SYNDEO Medical is driving a revolution in healthcare packs, visit www.syndeomedical.be 
Further information about the “20 Most innovative Companies to Watch, 2023” Awards can be found at  https://www.bwmonline.com/awards/20-most-innovative-companies-to-watch-2023-winners/ 
About Business Worldwide Magazine
Business Worldwide Magazine is the leading source of business and dealmaker intelligence throughout the world. Our quarterly magazine and online news portal enables an established audience of corporate dealmakers to track the latest news, stories and developments affecting the international markets, corporate finance, business strategy and changes in legislation. This readership includes of CEO/CFO – Banks, Corporate Lawyers and Venture Capital/Private Equity Companies to name a few.
ContactDavid Jones Awards DepartmentE: [email protected]W:  www.bwmonline.com
SOURCE Business Worldwide Magazine

Continue Reading →

FluidForm Bio Successfully Demonstrates Advancements in Engineered Heart Tissues with FRESH™ 3D Bioprinting

Coronary/Structural Heart by Comments are Disabled

WALTHAM, Mass., Dec. 12, 2023 /PRNewswire/ — FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting. Recently published in APL Bioengineering, the research article FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology addresses the critical need for a predictive model of human cardiac physiology in drug development. There are significant gaps in existing models due to their incomplete recapitulation of adult human cardiovascular physiology. FluidForm Bio has demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in three-dimensional tissue structure.
“We are not aware of any other biofabrication or tissue engineering approaches that can achieve comparable cell densities and uniaxial alignment on the market today, both of which contribute to more advanced physiologic function” said FluidForm Bio CTO and Co-founder Adam Feinberg.
The FRESH™ technology overcomes many of the limitations of other engineered cardiac tissues because it enables a high degree of cardiomyocyte alignment while minimizing hypoxia and cell death. Furthermore, by leveraging robotic fabrication, tissues are highly viable and reproducible, maintaining functional response across tissues and batches.
“This study was conducted by scientists at FluidForm and Merck & Co.,” explained FluidForm Bio CEO and Co-founder Mike Graffeo. “This is further evidence that we build the most lifelike tissue in the world with FRESH™. As we develop tissue therapeutic applications on this platform, we are thrilled to collaborate with top scientists and look forward to sharing further data.”
About FluidForm Bio FluidForm Bio is creating living human tissue for better treatment of disease. Our patented FRESH™ technology is a revolutionary platform designed to build tissue using cells, proteins, and nothing else. Through partnerships with top life science companies, our technology has been validated to produce the highest quality tissue in a variety of applications. We deliver human tissue that is indistinguishable from the real thing. Our living tissue will offer therapies to countless patients who deserve better treatment options.
FluidForm Bio was founded in 2018 on the belief that the world needs transformational technologies led by creative and passionate experts that help people lead better lives. Headquartered in Waltham, MA, learn more at http://www.fluidformbio.com/or connect on Twitter and LinkedIn.
Naomi Phaneuf, [email protected], 781-691-0978
SOURCE FluidForm Bio

Continue Reading →

West Physics Announces Acquisition of Radiation Protection Services, LTD.

Financial by Comments are Disabled

ATLANTA, Dec. 12, 2023 /PRNewswire/ — West Physics Consulting, LLC (“West Physics”), the leading national provider of integrated medical and health physics consulting services, announced today that it has completed the purchase of Radiation Protection Services, Ltd. (“RPS”), a respected regional provider of medical and health physics services based in Springfield, IL.
“We are thrilled to announce the acquisition of Radiation Protection Services. This strategic addition to West Physics helps us to expand our capabilities and capacity, and will further enhance our service delivery in Illinois, Missouri, Iowa, and Indiana. We welcome the RPS team to our organization and we look forward to achieving great success by combining forces and adding RPS’ radioactive material and imaging equipment testing skills and experience to the West Physics platform,” stated Dr. Geoffrey West, President & Chief Executive Officer of West Physics.
RPS customers are expected to benefit from the stability and support of the nation’s top medical and health physics provider. RPS customers will now have access to subject matter expertise in the areas of MRI safety, CT and fluoroscopy dose optimization, and clinical image analysis and review for ACR accreditation. Additionally, West Physics is excited to bring their world-class online training and reports portals to the RPS client base. Finally, the combination will result in increased scheduling flexibility, faster report turnaround, and enhanced support for customers.
“We’ve looked at a number of options over the last few years to help us take RPS to the next level in terms of growth and sophistication, and more importantly, to allow us to serve our customers even better,” said Doug Neuweg, President of RPS. “Becoming a part of West Physics was the clear winning option. They have built an incredible reputation over the years for being innovative, smart, and reliable and for also being totally committed to customer service. Our team is excited to add the resources of West Physics to our operation and to have many more colleagues to help us and our customers going forward,” continued Mr. Neuweg.
This acquisition aligns with West Physics’ strategy to provide premier medical and health physics services nationwide and globally. With RPS now part of West Physics, our team has grown to over 130 professionals serving over 6,000 customer sites across all 50 states, U.S. territories, the Caribbean, and the Middle East. We continue to be the largest diagnostic medical physics consulting practice in the United States, enabling us to deliver unparalleled quality and value for our customers.
About West Physics:
West Physics, headquartered in Atlanta, Georgia, is a global provider of medical and health physics testing and radiation safety consulting services. West Physics serves over 6,000 client sites, including hospitals, freestanding imaging centers, mobile imaging providers, and physician offices throughout the 50 U.S. states, federal territories, the Caribbean and the Middle East. West Physics specializes in assisting healthcare providers in maintaining their accreditation with organizations such as The Joint Commission, the American College of Radiology, the Intersocietal Accreditation Commission, and in radiation regulatory compliance with state and federal agencies. For more information, please visit http://www.westphysics.com.
About Radiation Protection Services, Ltd.:
Founded in 1986, Radiation Protection Services, Ltd. (“RPS”) is a privately owned company that provides radiation physics testing and consulting services for medical and industrial facilities that utilize x-ray-producing equipment or radioactive materials. RPS provides services to customers in Illinois, eastern Missouri, southeastern Iowa, and western Indiana, providing flexible and rapid response times along with personalized service. RPS staff specialize in ensuring regulatory compliance and radiation safety for their customers and their customers’ patients.
Media Contact: Denny Runnion, denny@westphysics.com
SOURCE West Physics Consulting, LLC

Continue Reading →

Karoo Health Validates Its Cardiac Value-based Care Model With High Patient Conversion and Engagement, and Cost Savings Through ED Diversions

Financial by Comments are Disabled

Industry-leading conversion to and engagement with Karoo’s unique wraparound cardiac care model led to emergency department diversion in 20% of patients during proof-of-concept period
ALBUQUERQUE, N.M., Dec. 12, 2023 /PRNewswire/ — Karoo Health, the only operational provider of cardiac value-based care (VBC) enablement, today released results of its first proof of concept (POC) with participating cardiac providers. Study data was collected from June through November 2023. Among the findings:

70% of eligible patients were converted to the Karoo VBC model in the most recent month of the POC period
95% digital engagement rate was demonstrated among enrolled patients throughout the POC period
20% of the patient panel was diverted from unnecessary ED visits during the POC period, leading to significant cost-of-care savings

Karoo seamlessly integrates dedicated on-site and virtual care teams with proprietary technology to facilitate the transition to, and success in, value-based care for cardiology providers, networks, health plans, and at-risk primary care groups. Karoo’s innovative enablement model is essential for enhancing patient health, reducing overall cost of care, and amplifying performance in HEDIS and Stars measures.
“Our proof of concept affirms the effectiveness of our cardiac VBC model,” said Karoo COO Chentelle Lane. “Our recent conversion rates exceeding 70 percent of eligible patients, compared to the 25 to 30 percent typically observed in other VBC companies, along with an impressive digital patient-engagement rate of 95 percent, underscore our unwavering commitment to execution and making a significant impact on the current and future state of cardiac care. Karoo is the only operational company using VBC to improve patient outcomes and lower cost of care in cardiovascular disease.”
“Karoo is making a difference in our overall approach to patient care,” said Harvey White, M.D., Founder and Executive Director of Vessel Health, an innovative provider of cardiovascular care in Albuquerque, N.M. “Karoo effortlessly integrates with our staff’s considerable medical expertise with supporting care teams and complementary technologies to break down barriers to better health by giving our providers more time to focus on important clinically-driven interactions.”
Karoo operations are led by a team of seasoned healthcare industry veterans, with Chentelle Lane serving as the Chief Operating Officer. Lane, who previously held the position of COO of Care Services at Cityblock Health, brings a wealth of experience from executive roles at Somatus and naviHealth. Complementing this expertise, Karoo has assembled an impressive team that has helped craft and lead some of the most prominent VBC companies in the industry, including Main Street Health, naviHealth, and Contessa Health.
About Karoo HealthHeart disease is currently the leading cause of death in the United States, with one person dying every 33 seconds due to cardiovascular illness. Employing an exclusive mix of specialized care teams and proprietary technology grounded in value-based principles, Karoo enables cardiology providers, networks, health plans, and at-risk primary care groups to seamlessly transition to, and succeed in, value-based care, and excel in outcomes-driven initiatives crucially required within the cardiac domain. For more information, visit the company at www.karoohealth.com or connect with them on LinkedIn.
SOURCE Karoo Health

Continue Reading →

CathVision Unveils ECGenius 3.1 To Improve Workflows and Optimize EGM AI Analyses

Coronary/Structural Heart by Comments are Disabled

Software Release Affirms CathVision’s Dedication to Advancing Data-Driven Clinical Diagnosis and TreatmentCOPENHAGEN, Denmark, Dec. 12, 2023 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the launch of ECGenius 3.1, an advanced version of the ECGenius™ System software. The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.1

Continue Reading

Intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.

Post this

ECGenius 3.1 is an advanced version of the ECGenius System software. The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data

ECGenius 3.1 delivers several new and enhanced features to provide an improved user experience throughout, including:

Advanced trigger function with automatic calipers for precise local activation analyses
Enhanced comparison functionality featuring pre-sized multiple windows for virtually effortless electrogram comparisons
Increased display sweep speed of up to 800 mm/s to help identify crucial EGM details
Expanded and improved connectivity with RF generators and large monitor displays

The release of ECGenius 3.1 follows the Q3 launch of the PVI Analyzer™ and Signal Complexity™ algorithms. These algorithms are part of the CARDIALYTICS™ suite of artificial intelligence-powered analytics integrated into the ECGenius System, making it the only EP recording system with an AI algorithm to facilitate electrogram interpretation and deliver unprecedented levels of intelligent, automated analyses designed to help physicians improve ablation outcomes in complex atrial arrhythmia procedures by measuring the success of cardiac ablation.2″The enhanced features and overall clinical maturity of ECGenius 3.1 clearly demonstrate this state-of-the-art EP recording system will provide advanced clinical utility to the broader EP community throughout the US,” said Dr. Larry Chinitz, Director of Electrophysiology at NYU Langone Health. “EPs are looking for opportunities to take our work to a higher level, and there is no other recording system better positioned to help us do that. We now have the technology to replace outdated systems.””These consecutive, major software launches highlight CathVision’s considerable momentum and our expertise in developing software features that streamline procedure workflows and enhance the physician experience,” said Mads Matthiesen, CEO, CathVision. “EPs are eager to access better quality signal data. ECGenius 3.1 makes the workflow transition seamless and strengthens our leadership position in equipping electrophysiologists with the technology necessary to elevate patient outcomes.”ECGenius System is CathVision’s innovative EP recording technology and proprietary hardware amplifier that acquires high-fidelity, low-noise cardiac electrograms to help electrophysiologists improve the diagnosis and treatment of complex atrial arrhythmias, including AF. Unlike traditional EP recording systems that often capture electrogram signals marred by noise and artifact, ECGenius delivers a necessary evolution in the quality of intracardiac and ECG signal acquisition, the accuracy of electrogram interpretation, and the advancement of therapy support. With exceptional data from the ECGenius System, intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.For more information about ECGenius System and CARDIALYTICS, please visit www.cathvision.com or email [email protected].About CathVisionCathVision is a medical technology company that develops electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform – the ECGenius System with CARDIALYTICS. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize, and treat the most common heart rhythm disorders. CathVision was founded in 2013 and is headquartered in Denmark with a U.S. office in Minnesota.Follow CathVision: Twitter/X and LinkedIn 1 ECGenius System is cleared for sale in the US. Not approved for sale in the rest of the world. 2 PVI Analyzer and Signal Complexity are cleared for sale in the US. Not approved for sale in the rest of the world.SOURCE CathVision

Continue Reading →
1 … 317 318 319 320 321 … 1,346